22 February 2023 in Science Translational Medicine
Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a Simon’s minmax two-stage, single-arm, phase 2 clinical trial (NCT03208413) to assess the efficacy of thalidomide in patients with RIBI who were unresponsive to or had contraindications to bevacizumab and corticosteroid therapies. The trial met its primary endpoint, with 27 of 58 patients enrolled showing ≥25% reduction in the volume of cerebral edema on fluid-attenuated inversion recovery–magnetic resonance imaging (FLAIR-MRI) after treatment (overall response rate, 46.6%; 95% CI, 33.3 to 60.1%). Twenty-five (43.1%) patients demonstrated a clinical improvement based on the Late Effects Normal Tissues–Subjective, Objective, Management, Analytic (LENT/SOMA) scale, and 36 (62.1%) experienced cognitive improvement based on the Montreal Cognitive Assessment (MoCA) scores. In a mouse model of RIBI, thalidomide restored the blood-brain barrier and cerebral perfusion, which were attributed to the functional rescue of pericytes secondary to elevation of platelet-derived growth factor receptor β (PDGFRβ) expression by thalidomide. Our data thus demonstrate the therapeutic potential of thalidomide for the treatment of radiation-induced cerebral vasculature impairment.
1 November 2025 in Stroke
BACKGROUND: Randomized trials have demonstrated the benefit of endovascular treatment (EVT) in moderate-to-severe acute basilar artery occlusion (BAO), but its benefit in acute mild BAO remains uncertain. This multicenter, retrospective cohort study aimed to explore the efficacy of EVT in acute BAO with a low National Institutes of Health Stroke Scale. METHODS: Patients with acute BAO and National Institutes of Health Stroke Scale <10, hospitalized at 5 stroke centers in China between January 2020 and December 2023, were included and divided into EVT and standard medical treatment groups. The primary outcome was 90-day functional independence, defined as a modified Rankin Scale score of 0 to 2. Secondary outcomes include proportions of 90-day modified Rankin Scale score of 0 to 1 and 0 to 3. Symptomatic intracerebral hemorrhage within 48 hours and 90-day mortality were assessed as safety outcomes. RESULTS: Three hundred fifteen patients with BAO with National Institutes of Health Stroke Scale <10 were enrolled (229 [72.7%] male; median [interquartile range] age, 65 [58–72] years; median [interquartile range] baseline National Institutes of Health Stroke Scale score, 6 [3–8] points), 161 (51.1%) of whom underwent EVT and 154 (48.9%) received standard medical treatment. The EVT group had a higher rate of 90-day functional independence (68.9% versus 44.8%; adjusted odds ratio, 3.69 [95% CI, 2.04–6.68]; P <0.001). There was no significant difference in 90-day mortality (4.3% versus 4.5%; adjusted odds ratio, 1.22 [95% CI, 0.37–4.03]; P =0.80). However, EVT was associated with a higher risk of symptomatic intracerebral hemorrhage (8.2% versus 3.9%; adjusted odds ratio, 3.86 [95% CI, 1.18–12.61]; P =0.03). CONCLUSIONS: In this cohort of patients with acute mild BAO, EVT was associated with an improved 90-day functional outcome compared with standard medical treatment alone, although the risk of symptomatic intracerebral hemorrhage was increased.
18 April 2022 in Cellular and Molecular Neurobiology
25 April 2025 in IEEE Transactions on Biomedical Engineering
Sleep spindles, which are key biomarkers of non-rapid eye movement stage 2 sleep, play a crucial role in predicting outcomes for patients with acute disorders of consciousness (ADOC). However, several critical challenges remain in spindle detection: 1) the limited use of automated spindle detection in ADOC; 2) the difficulty in identifying low-frequency spindles in patient populations; and 3) the lack of effective tools for quantitatively analyzing the relationship between spindle density and patient outcomes. To address these challenges, we propose a novel Deep Learning-Augmented algorithm for automated sleep spindle detection in ADOC patients. This method combines Convolutional Neural Networks with decision tree-assisted validation, using wavelet transform principles to enhance detection accuracy and sensitivity, especially for the slow spindles commonly found in ADOC patients. Our approach not only demonstrates superior performance and reliability but also has the potential to significantly improve diagnostic precision and guide treatment strategies when integrated into clinical practice. Our algorithm was evaluated on the Montreal Archive of Sleep Studies - Session 2 (MASS SS2, n = 19), achieving average F1 scores of 0.798 and 0.841 compared to annotations from two experts. On a self-recorded dataset from ADOC patients (n = 24), it achieved an F1 score of 0.745 compared to expert annotations. Additionally, our analysis using the Spearman correlation coefficient revealed a moderate positive correlation between sleep spindle density and 28-day Glasgow Outcome Scale scores in ADOC patients. This suggests that spindle density could serve as a prognostic marker for predicting clinical outcomes and guiding personalized patient care.
27 February 2026 in European Journal of Pharmacology